Pull 4 Parkinson’s Foundation, Inc., a registered 501(c)(3) public charity,
funds cure and care research conducted by the Parkinson's disease community.
Learn More or Donate.

Amarantus BioSciences, Inc. (OTC:AMBS) on Close Watch

Amarantus BioSciences, Inc. (OTC:AMBS) made a spectacular move up earlier this year from lows of $0.004 to highs of $0.09 per share. Smart investors who got in early made explosive gains.

Since then the stock has dropped considerably and now sits just below $0.03 with all the positive developments in recent months investors are hoping AMBS can regain its previous highs.

Amarantus Bioscience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.

AMBS owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor; MANF and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.

AMBS run was due in part to the appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. Dr. Rubinfeld will assist management in positioning the Company's development programs for partnering, as well as provide guidance on MANF-based small molecule strategies with his extensive medicinal chemistry background.

"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen"

OTCMAGIC has recently published a new article on AMBS. To find out more about this stock and what OTCMAGIC projects for Amarantus BioSciences both short term and long term please go here: AMBS

OTCMAGIC Spends all day scouring the markets for the next huge Penny Stock Winner. Investors have come to trust us for our up to date commentary on all hot stocks so please visit OTCMAGIC right now and see what it’s all about for yourself! At 30,000 Visitors a Month and growing rapidly OTCMAGIC is the hottest thing in Penny Stocks!

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PLEASE NOTE: OTCMagic.com employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at http://OTCMagic.com/disclaimer. Release of Liability: Through use of this website viewing or using you agree to hold OTCMagic.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. OTCMagic.com affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCMagic.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCMagic.com. We make no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. This is not a solicitation to buy or sell any securities. Any claims or Statements should be deemed hypothetical. OTCMagic.com, nor any of its affiliates are not registered investment advisors or broker dealers.

Media Relations Contact

Marco Magic
775-581-4290
Email | Web

Comments

Article’s News Categories:

Related Articles: